Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, rose in value, with the stock price down by -1.28% to the previous day’s close as strong demand from buyers drove the stock to $135.99.
Actively observing the price movement in the last trading, the stock closed the session at $137.76. The PE ratio was 55.96 over 12-month period. Referring to stock’s 52-week performance, its high was $148.37, and the low was $89.04. On the whole, NBIX has fluctuated by -1.33% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 2.21B, with a low estimate of 491.5M and a high estimate of 528M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 511.97M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NBIX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 3.11, with the price of NBIX currently trading nearly -0.42% and -0.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 48.69, while the 7-day volatility ratio is showing 3.16% which for the 30-day chart, stands at 2.76%. Furthermore, Neurocrine Biosciences, Inc. (NBIX)’s beta value is 0.28, and its average true range (ATR) is 4.27.
A comparison of Neurocrine Biosciences, Inc. (NBIX) with its peers suggests the former has fared considerably weaker in the market. NBIX showed an intraday change of -1.28% in last session, and over the past year, it grew by 32.39%%.
Data on historical trading for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) indicates that the trading volumes over the past 3 months, they’ve averaged 883.22K. According to company’s latest data on outstanding shares, there are 98.70 million shares outstanding.
Nearly 2.60% of Neurocrine Biosciences, Inc.’s shares belong to company insiders and institutional investors own 92.81% of the company’s shares. The stock has risen by 3.21% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NBIX stock heading into the next quarter.
